Results 131 to 140 of about 6,956,776 (231)
Hospital pharmacists' perceptions, needs, barriers, and facilitators of pharmacy practice research in China: a qualitative study. [PDF]
Zhang C, Wu Y, Li X.
europepmc +1 more source
Aim Pancreatic enzyme replacement therapy (PERT) is essential for the management of pancreatic exocrine insufficiency. Since June 2023, the United Kingdom has been affected by a global shortage of PERT. We investigated the impact of this shortage on national prescribing trends for Creon, Nutrizym, Pancrex and Pangrol.
Teena S. Varghese +6 more
wiley +1 more source
A full review of online OPAT educational resources for patients and healthcare professionals in the grey literature revealing resource gaps. [PDF]
Watson C +8 more
europepmc +1 more source
Aims Clozapine is the most effective antipsychotic in treatment‐resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated.
Susanna Maria Rask +6 more
wiley +1 more source
Pharmacist-led Transitions of Care Intervention to Address Infectious Disease Tests Pending at Discharge (TPAD). [PDF]
Covington EW +5 more
europepmc +1 more source
Indeks Pharmacy vol. 13 no 1, Juli 2016 dan Panduan Penulisan Pharmacy
Indeks Pharmacy vol.
Pharmacy, Admin
core
Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon +7 more
wiley +1 more source
Reshaping Smart Pharmacy in TCM Hospitals via High-Reliability Organization Theory. [PDF]
Cai T +10 more
europepmc +1 more source
A British Pharmacological Society Position Statement on Medications in Pregnancy and Lactation
British Journal of Clinical Pharmacology, EarlyView.
Agnesa Mustafa +14 more
wiley +1 more source
After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon +11 more
wiley +1 more source

